A prospective observational study of osimertinib as predictive marker against patients with EGFR mutation positive NSCLC.
Not Applicable
Recruiting
- Conditions
- ung Cancer
- Registration Number
- JPRN-UMIN000040432
- Lead Sponsor
- Gunma University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)Active double cancer 2)Interstitial pneumonitis on chest CT 3)Active infectious disease 4) Not approbed for blood sampling 5) Plegnant woman
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint:To predict the efficacy of osimertinib according to quantitative amount ofEGFR mutation expression. Secandary endpoint:To predict the efficacy of osimertinib according to quantitative amount of C797S.
- Secondary Outcome Measures
Name Time Method